Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

被引：0
|
作者：
Atsuo Takashima
Kohei Shitara
Kazumasa Fujitani
Keisuke Koeda
Hiroki Hara
Norisuke Nakayama
Shuichi Hironaka
Kazuhiro Nishikawa
Yutaka Kimura
Kenji Amagai
Hirofumi Fujii
Kei Muro
Taito Esaki
Yasuhiro Choda
Toshimi Takano
Keisho Chin
Atsushi Sato
Masahiro Goto
Norimasa Fukushima
Takuo Hara
Nozomu Machida
Manabu Ohta
Narikazu Boku
Masashi Shimura
Satoshi Morita
Wasaburo Koizumi
机构：
[1] National Cancer Center Hospital,Gastrointestinal Medical Oncology Division
[2] National Cancer Center Hospital East,Department of Gastrointestinal Oncology
[3] Osaka General Medical Center,Department of Surgery
[4] Iwate Medical University School of Medicine,Department of Surgery
[5] Saitama Cancer Center,Department of Gastroenterology
[6] Kanagawa Cancer Center,Department of Gastroenterology
[7] Chiba Cancer Center,Clinical Trial Promotion Department
[8] National Hospital Organization Osaka National Hospital,Department of Surgery
[9] Sakai City Medical Center,Department of Surgery
[10] Ibaraki Prefectural Central Hospital,Department of Gastroenterology
[11] Jichi Medical University Hospital,Department of Clinical Oncology
[12] Aichi Cancer Center Hospital,Department of Clinical Oncology
[13] National Kyushu Cancer Center,Department of Gastrointestinal and Medical Oncology
[14] Hiroshima City Hiroshima Citizens Hospital,Department of Surgery
[15] Toranomon Hospital,Department of Medical Oncology
[16] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,Department of Gastroenterology
[17] Hirosaki University Graduate School of Medicine,Department of Medical Oncology
[18] Osaka Medical College Hospital,Cancer Chemotherapy Center
[19] Yamagata Prefectural Central Hospital,Department of Surgery
[20] Kouseiren Takaoka Hospital,Department of Surgery
[21] Shizuoka Cancer Center,Division of Gastrointestinal Oncology
[22] Hamamatsu University School of Medicine,Oncology Center
[23] Taiho Pharmaceutical. Co.,Data Science Department
[24] Ltd.,Department of Biomedical Statistics and Bioinformatics
[25] Kyoto University Graduate School of Medicine,Department of Gastroenterology
[26] Kitasato University School of Medicine,undefined
来源：
Gastric Cancer | 2019年 / 22卷
关键词：
Peritoneal metastasis; Nab-paclitaxel; Solvent-based paclitaxel; Second-line chemotherapy; Predictive factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：155 / 163
页数：8
相关论文
共 50 条
  • [31] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer A Phase 2 Randomized Clinical Trial
    Karasic, Thomas B.
    O'Hara, Mark H.
    Loaiza-Bonilla, Arturo
    Reiss, Kim A.
    Teitelbaum, Ursina R.
    Borazanci, Erkut
    De Jesus-Acosta, Ana
    Redlinger, Colleen
    Burrell, Jessica A.
    Laheru, Daniel A.
    Von Hoff, Daniel D.
    Amaravadi, Ravi K.
    Drebin, Jeffrey A.
    O'Dwyer, Peter J.
    JAMA ONCOLOGY, 2019, 5 (07) : 993 - 998
  • [33] Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
    Olawaiye, Alexander B.
    Kim, Jae-Weon
    Bagameri, Andrea
    Bishop, Erin
    Chudecka-Glaz, Anita
    Devaux, Alix
    Gladieff, Laurence
    Gordinier, Mary E.
    Korach, Jacob
    McCollum, Michael E.
    Mileshkin, Linda
    Monk, Bradley J.
    Nicum, Shibani
    Nogueira-Rodrigues, Angelica
    Oaknin, Ana
    O'Malley, David M.
    Orlando, Mauro
    Dreiling, Lyndah
    Tudor, Julia C.
    Lorusso, Domenica
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (04)
  • [34] SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
    Hidalgo, Manuel
    Plaza, Carlos
    Musteanu, Monica
    Illei, Peter
    Brachmann, Carrie B.
    Heise, Carla
    Pierce, Daniel
    Lopez-Casas, Pedro P.
    Menendez, Camino
    Tabernero, Josep
    Romano, Alfredo
    Wei, Xinyu
    Lopez-Rios, Fernando
    Von Hoff, Daniel D.
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4811 - 4818
  • [35] NAB-PACLITAXEL IN THE TREATMENT OF ADVANCED PANCREATIC CANCER REFRACTORY TO GEMCITABINE - FINAL RESULTS OF A PHASE 2 TRIAL
    Lopes, G. de Lima
    Hosein, P.
    Gomez, C.
    Pastorini, V.
    Macintyre, J.
    Easey, M.
    Reis, I.
    Merchan, J.
    Bejarano, P.
    Rocha-Lima, C.
    EJC SUPPLEMENTS, 2011, 9 (01): : 1 - 1
  • [36] Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
    Yamamoto, Tomohisa
    Fujii, Tsutomu
    Hirano, Satoshi
    Motoi, Fuyuhiko
    Honda, Goro
    Uemura, Kenichiro
    Kitayama, Joji
    Unno, Michiaki
    Kodera, Yasuhiro
    Yamaue, Hiroki
    Shimokawa, Toshio
    Hashimoto, Daisuke
    Yamaki, So
    Yoshitomi, Hideyuki
    Miura, Fumihiko
    Ueno, Hideki
    Sekimoto, Mitsugu
    Satoi, Sohei
    TRIALS, 2022, 23 (01)
  • [37] Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
    Tomohisa Yamamoto
    Tsutomu Fujii
    Satoshi Hirano
    Fuyuhiko Motoi
    Goro Honda
    Kenichiro Uemura
    Joji Kitayama
    Michiaki Unno
    Yasuhiro Kodera
    Hiroki Yamaue
    Toshio Shimokawa
    Daisuke Hashimoto
    So Yamaki
    Hideyuki Yoshitomi
    Fumihiko Miura
    Hideki Ueno
    Mitsugu Sekimoto
    Sohei Satoi
    Trials, 23
  • [38] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [39] Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
    Mahipal, Amit
    Springett, Gregory M.
    Burke, Nancy
    Bertels, Barbara
    Wapinsky, Georgine
    Almhanna, Khaldoun
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [40] A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer
    Sato, Sho
    Kunisaki, Chikara
    Tanaka, Yusaku
    Sato, Kei
    Miyamoto, Hiroshi
    Yukawa, Norio
    Fujii, Yoshiro
    Kimura, Jun
    Takagawa, Ryo
    Takahashi, Masazumi
    Kosaka, Takashi
    Akiyama, Hirotoshi
    Saigusa, Yusuke
    Taguri, Masataka
    Yamanaka, Takeharu
    Endo, Itaru
    ANTICANCER RESEARCH, 2018, 38 (12) : 6911 - 6917
12345